Immunogenicity of a Modified Microcrystalline Tyrosine (MCT

Ragweed pollinosis is well documented in both the United States and Europe with 26.2% of an American sample population shown to give positive skin prick test reactions to short Ragweed pollen [1]. The clinical manifestations of this sensitisation can be commonly shown as rhinitis, rhinoconjunctivitis and in severe cases allergic asthma. The benefits of specific immunotherapy for the treatment of rhinoconjunctivitis compared to symptomatic treatment has been demonstrated clinically and offers sustained effects and a decreased risk of developing the more severe allergic asthma [2, 3]. Treatment of pollinosis with allergoids absorbed to MCT ® has been shown to be safe and efficacious, both with and without the adjuvant MPL ® [4]. The immunogenicity study described in this paper further characterises the efficacy of these allergoids absorbed to MCT ®